Veradigm, a leading healthcare technology company, has announced a significant advancement in real-world evidence (RWE) generation for GLP-1 receptor agonists (GLP-1 RAs) by incorporating artificial intelligence (AI) into its data processing methods. This innovative approach leverages a nationwide network of de-identified electronic health records (EHRs) to extract valuable clinical insights from large datasets, including side effects, reasons for treatment discontinuation, and social determinants of health (SDoH). These insights are crucial for enhancing the understanding and application of GLP-1 therapies, which have shown revolutionary potential in managing type 2 diabetes and obesity but still face substantial unknowns in real-world settings. GLP-1 RAs, including drugs like semaglutide and tirzepatide, have transformed the treatment landscape for type 2 diabetes and obesity, offering effective management options. However, their practical usage presents several challenges, notably in identifying why some patients discontinue treatment and the specific side effects that affect them the most. Traditionally, this information has been buried in unstructured data, such as physician notes, requiring extensive manual curation. To address these gaps, Veradigm's AI-driven solution automates the extraction of clinical signals from unstructured and semi-structured EHR data. The system can process millions of patient records efficiently, revealing hidden details that are essential for improving patient outcomes and optimizing drug strategies. According to Stuart Green, Veradigm's Senior Vice President and General Manager of Life Sciences, "AI-driven data organization enables us to unlock meaningful clinical insights from massive patient records. Understanding why patients drop out or which side effects are most impactful is vital for enhancing treatment efficacy and refining therapeutic approaches." The AI technology at Veradigm operates on several key principles: Comprehensive Data Coverage: Veradigm's network encompasses a wide range of EHR data from diverse patient populations across various regions, ensuring a comprehensive and representative dataset. High-Precision Data Validation: The system integrates machine learning with clinical validation to ensure data accuracy and relevance, making it suitable for life science research, regulatory interactions, and value-based decision-making. Efficient Insight Extraction: AI algorithms automatically identify and organize critical clinical information, significantly reducing the time and resources needed for manual data review. Scheduled for May 14, 2025, Veradigm will present its findings at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) conference during the poster session from 4:00 PM to 7:00 PM EST. The presentation will focus on GLP-1 treatment persistence and the real-world reasons for treatment discontinuation, providing a deeper understanding of patient behavior and therapeutic outcomes. Interested attendees can access the poster abstract via the conference website. Founded in 2018, Veradigm is a subsidiary of MDRX (the American Association of Pharmaceutical Research and Development), dedicated to delivering technology-driven solutions for healthcare providers, payers, and the biopharma market. The company's mission is to "wisely change health" through advanced analytics and insights derived from its robust data platform. More information about Veradigm's services and mission can be found on its official website or on its social media channels like LinkedIn, Facebook, and Twitter. Industry experts are praising Veradigm's initiative, highlighting its potential to revolutionize the field of healthcare data analysis. They believe that AI-powered solutions like Veradigm's can significantly enhance the efficiency and depth of clinical studies, enabling faster discovery of new therapeutic potentials and potential issues. By providing real-time, detailed insights into patient experiences and treatment outcomes, Veradigm is poised to play a pivotal role in the development and optimization of future medical treatments. In conclusion, Veradigm's AI-driven EHR data processing is a game-changing innovation that addresses critical gaps in real-world evidence for GLP-1 therapies. The technology's ability to efficiently extract and validate clinical insights from vast amounts of unstructured data will not only improve patient outcomes but also accelerate the progression of life science research. As AI continues to evolve, more companies are expected to follow Veradigm's lead, fostering a new era of data-driven healthcare advancements. Veradigm's strong track record and extensive partnerships position it as a leader in this transformative space, further solidifying its role in shaping the future of healthcare technology and patient care.